Standard Biotools Inc (LAB)
NASDAQ:LAB
Top Page
Standard BioTools
(NASDAQ:LAB)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.88
▼(-37.30% Downside)
Action:ReiteratedDate:02/25/26
The score is held down primarily by weak financial performance (volatile/declining revenue, large ongoing losses, and persistent negative free cash flow) and bearish technical signals (price below key moving averages with negative MACD). Corporate events modestly improve the outlook via increased cash and operational streamlining, but valuation support is limited because losses make P/E less informative and there is no dividend yield.
Positive Factors
Material cash infusion from SomaLogic divestiture
Completing the SomaLogic divestiture delivered roughly $550M in cash and investments, materially improving liquidity. This structural capital buffer supports M&A or product investment, reduces near-term solvency pressure and underpins the stated path to adjusted EBITDA profitability in 2026.
Negative Factors
Persistent and significant cash burn
Consistent negative operating and free cash flow means the business cannot self-fund operations and relies on external financing or asset sales. Over the medium term this constrains R&D, commercialization and working-capital flexibility and raises dilution and refinancing risks if losses persist.
Read all positive and negative factors
Positive Factors
Negative Factors
Material cash infusion from SomaLogic divestiture
Completing the SomaLogic divestiture delivered roughly $550M in cash and investments, materially improving liquidity. This structural capital buffer supports M&A or product investment, reduces near-term solvency pressure and underpins the stated path to adjusted EBITDA profitability in 2026.
Read all positive factors
Standard BioTools (LAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$345.33M
Dividend YieldN/A
Average Volume (3M)2.33M
Price to Earnings (P/E)6.4
Beta (1Y)1.57
Revenue Growth-17.37%
EPS Growth52.28%
CountryUS
Employees814
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.04
Shares Outstanding390,071,500
10 Day Avg. Volume1,640,121
30 Day Avg. Volume2,329,110
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.15
Price to Sales (P/S)5.72
P/FCF Ratio-5.91
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue3.02
Enterprise Value/Gross Profit6.06
Enterprise Value/Ebitda-3.01
Forecast
1Y Price Target
$1.35Price Target Upside-4.26% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-0.12
Revenue Forecast (FY)$79.73M
Standard BioTools Business Overview & Revenue Model
Company Description
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle Ea...
How the Company Makes Money
Standard BioTools makes money primarily by selling and supporting life science research tools and the consumables required to run them. Its revenue model generally includes: (1) Instrument and system sales: One-time sales of research instruments a...
Standard BioTools Key Performance Indicators (KPIs)
Standard BioTools Earnings Call Summary
Earnings Call Date:May 06, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Neutral
The earnings call reflected a well-managed quarter with robust strategic initiatives and strong cost management, despite facing significant revenue declines and challenges in the U.S. academic market. The company's strong cash position and strategic product expansions provide a positive outlook, though the impact of tariffs and revenue declines remain concerns.Positive Updates
Strategic Product Launches and Expansions
Standard BioTools announced a new SomaScan offering and expanded its reach with the NGS-based Illumina partner solution, enhancing translational and clinical research capabilities.
Negative Updates
Revenue Decline
Total revenue fell by 10% year-over-year, with consumables down by 16% and services down by 16%, due to lower volumes and project timing.
Read all updates
Q1-2025 Updates
Positive
Negative
Strategic Product Launches and Expansions
Standard BioTools announced a new SomaScan offering and expanded its reach with the NGS-based Illumina partner solution, enhancing translational and clinical research capabilities.
Read all positive updates
Company Guidance
During the Standard BioTools first quarter 2025 earnings call, the company reiterated its full-year revenue guidance of $165 million to $175 million, despite a 10% year-over-year decline in Q1 revenue to $40.8 million. The decline was primarily due to lower consumables and services revenue, with consumables down 16% and services down 16% year-over-year. Instrument sales, however, grew by 24%, driven by the Hyperion XTi system. The company reported non-GAAP gross margins of 53.2%, impacted by lower volumes and product mix, and a non-GAAP operating loss improvement of 45% year-over-year. Adjusted EBITDA loss improved 29% to $16.9 million, and cash burn was reduced by 33%. The company emphasized its strategic focus on proteomics and highlighted new product launches, including the CyTOF-XT Pro and SomaScan Select Asset, as key drivers for future growth.Standard BioTools Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
52
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 85.33M | 174.43M | 106.34M | 97.95M | 130.58M |
| Gross Profit | 42.54M | 84.26M | 50.45M | 37.05M | 69.37M |
| EBITDA | -94.96M | -118.14M | -54.46M | -173.57M | -44.27M |
| Net Income | -74.90M | -138.88M | -74.66M | -190.10M | -59.24M |
Balance Sheet | |||||
| Total Assets | 567.75M | 612.34M | 323.07M | 390.31M | 275.21M |
| Cash, Cash Equivalents and Short-Term Investments | 187.57M | 292.87M | 114.89M | 165.78M | 28.45M |
| Total Debt | 30.83M | 33.00M | 98.21M | 102.66M | 111.65M |
| Total Liabilities | 143.46M | 140.62M | 471.12M | 471.78M | 180.62M |
| Stockholders Equity | 424.29M | 471.72M | -148.05M | -81.47M | 94.60M |
Cash Flow | |||||
| Free Cash Flow | -82.65M | -151.81M | -46.12M | -93.19M | -57.33M |
| Operating Cash Flow | -74.35M | -143.45M | -43.29M | -89.37M | -44.06M |
| Investing Cash Flow | 24.77M | 363.17M | 20.24M | -88.13M | -11.95M |
| Financing Cash Flow | 570.00K | -102.62M | -6.81M | 230.76M | 15.96M |
Standard BioTools Technical Analysis
Negative
1.41
Price Trends
1.07
Negative
1.26
Negative
1.27
Negative
Market Momentum
-0.05
Negative
33.43
Neutral
39.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LAB, the sentiment is Negative. The current price of 1.41 is above the 20-day moving average (MA) of 0.94, above the 50-day MA of 1.07, and above the 200-day MA of 1.27, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 33.43 is Neutral, neither overbought nor oversold. The STOCH value of 39.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LAB.
Standard BioTools Risk Analysis
Standard BioTools disclosed 49 risk factors in its most recent earnings report. Standard BioTools reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Standard BioTools Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $696.60M | -46.67 | -5.27% | ― | 10.15% | -295.52% | |
56 Neutral | $822.02M | -47.01 | -6.47% | ― | 14.46% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $469.08M | -8.63 | -5.40% | ― | 13.60% | 74.64% | |
49 Neutral | $637.21M | -8.74 | -39.13% | ― | -21.02% | 47.74% | |
48 Neutral | $415.18M | -1.57 | -79.81% | ― | 0.21% | -233.51% | |
44 Neutral | $345.33M | 6.39 | -17.59% | ― | -17.37% | 52.28% |
* Healthcare Sector Average
LAB
Standard BioTools
0.89
-0.26
-23.04%
MYGN
Myriad Genetics
4.35
-3.73
-46.16%
CDNA
CareDx
16.05
-2.85
-15.08%
FLGT
Fulgent Genetics
14.43
-4.52
-23.85%
PSNL
Personalis
6.02
2.78
85.80%
CSTL
Castle Biosciences
23.13
3.24
16.29%
Standard BioTools Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Standard BioTools Details SomaLogic Sale and Profitability Path
Negative
Feb 24, 2026
Standard BioTools reported fourth-quarter 2025 revenue from continuing operations of $23.8 million and full-year revenue of $85.3 million, declines of 4% and 6% respectively, driven by weaker consumables and services demand amid funding and capita...
Business Operations and StrategyM&A Transactions
Standard BioTools Completes Major Proteomics Business Divestiture
Positive
Jan 30, 2026
On January 30, 2026, Standard BioTools completed the sale of its aptamer-based and functional proteomics business, including SomaLogic and Sengenics entities and the SomaScan, KREX and Single SOMAmer assay franchises, to Illumina for $350 million ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.